Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice : Episode 9
Treatment Strategy in Patients with Unresectable Stage I-III NSCLC
Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.
EP: 1.Overview of Early-Stage NSCLC and Molecular Testing
EP: 2.Selecting Optimal Treatment in Early-Stage NSCLC
EP: 3.Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study
EP: 4.Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study
EP: 5.Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies
EP: 6.Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC
EP: 7.Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC
EP: 8.Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies
Now Viewing
EP: 9.Treatment Strategy in Patients with Unresectable Stage I-III NSCLC
EP: 10.Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study
EP: 11.Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches
EP: 12.Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab
EP: 13.Practice Pearls for Community Oncologists Treating Early-Stage NSCLC
Related Videos
Related Content
